Cancer Medicines Outcomes Programme Public Health Scotland (CMOP-PHS) report for the Scottish Medicines Consortium (SMC)
First-line treatment of adults with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy: SMC2842

About this release

This release by Public Health Scotland (PHS) uses information from the National SACT dataset. This work was requested by the Scottish Medicines Consortium (SMC) to support their decision-making processes. Enfortumab vedotin in combination with pembrolizumab, for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy is being assessed for use by NHSScotland (SMC2842).

The aim of this work was to capture real-world evidence from Scotland on the use of Systemic Anti-Cancer Therapy (SACT) for first-line treatment of adults with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy. Details of the presumptions made to identify this cohort are described in Section 2.3.1. of the main report. This work will enable SMC members to assess the relevance of information, provided as part of the assessment process for SMC2842, to patients in Scotland.

The objectives of this work were to:

• Determine the number of patients prescribed first-line SACT for unresectable or metastatic urothelial cancer who were eligible for platinum-containing chemotherapy.
• Describe the baseline characteristics of patients prescribed first-line SACT for unresectable or metastatic urothelial cancer who were eligible for platinum-containing chemotherapy.
• Describe the first-line SACT regimens prescribed for unresectable or metastatic urothelial cancer in patients eligible for platinum-containing chemotherapy, including avelumab as a maintenance treatment.